Can Borui Biotech stand out in the treatment of lymphoma with the launch of its first biologically innovative drug, Zebedumab?

Tech 2023-07-06 12:50:35 Source: Network

21st Century Business Herald reporter Zhu Yiyi reports from ShanghaiThe launch of this new drug is not only a major milestone in the development of Brilliant Biology, but also provides new treatment options for domestic lymphoma patients.Multiple indicators with significant clinical efficacyAccording to public information, lymphoma is one of the common hematological malignancies

21st Century Business Herald reporter Zhu Yiyi reports from Shanghai

The launch of this new drug is not only a major milestone in the development of Brilliant Biology, but also provides new treatment options for domestic lymphoma patients.

Multiple indicators with significant clinical efficacy

According to public information, lymphoma is one of the common hematological malignancies. At present, the incidence rate of lymphoma in China is about 6.68/100000 people, with more than 100000 new cases every year. Among them, B-cell non Hodgkin lymphoma is one of the common types, and the number of cases and deaths are increasing year by year.

In addition, the market prospects for CD20 targets are broad.

According to Frost&Sullivan's report, in 2020, the market size of anti CD20 monoclonal antibodies in China will be 3.5 billion yuan, which is expected to reach 9.8 billion yuan and 22 billion yuan in 2025 and 2030, respectively. The compound annual growth rate from 2020 to 2025 is 23.1%, and the compound annual growth rate from 2025 to 2030 is 17.5%.

Against the above background, numerous pharmaceutical companies are vying to layout around the CD20, a "old but new" target.

In the face of fierce market competition, what are the advantages of Borui Bio's Zebedumab? Can we break through the tight encirclement?

"In 2007, we cooperated with Academician Shen Beifen, an academician of the CAE Member and an academic leader of molecular immunology, and his team to develop Zebetumab. After 16 years of research and development, the biological innovative drug was finally approved for marketing in 2023." On the sidelines of the national marketing conference of Anruixizebetumab, Wang Haibin, CEO of Braui Biology, pointed out in an interview with reporters from 21st Century Business Herald.

According to Wang Haibin, "Compared to other anti CD20 monoclonal antibody products, the cytotoxic effect (ADCC) mediated by Zebedizumab antibody is stronger, and it has a larger steady-state distribution volume, which can produce a more lasting clearance effect on B cells, thereby exerting better drug effects.

The commercialization progress and indication expansion of Zebedizumab are receiving attention

At this stage, Wang Haibin revealed that he will provide patients with greater access through charitable assistance.

For the development plan of other indications of zebetozumab, Wang Haibin said that the company would further expand the relevant indications of zebetozumab, "such as developing relevant indications for some subtypes of other B-cell lymphoma; in the future, we will also promote the field of autoimmunity, including developing relevant indications for primary immune thrombocytopenia (ITP), Rheumatoid arthritis (RA) and nephrology".

Focusing on self immunity and tumor pipelines

As an innovative biopharmaceutical enterprise, Borui Biotech focuses on the fields of autoimmune and tumor treatment, and differentiates its innovation pipeline. At present, the company has more than 20 main research products, of which more than 10 have entered the clinical stage, and 6 have been commercialized and listed.

The shareholders of Borui Biotech include well-known investment institution Taimeng Investment, A-share listed company Haizheng Pharmaceutical (600267. SH), and Taizhou State owned Asset Investment Group Co., Ltd.

In addition, BRY812, a class 1 new drug of Brevibios, is a new anti LIV-1ADC drug for breast cancer and the second targeted LIV-1ADC drug entering the clinical stage in the world.

For more information, please download the 21 Finance APP

Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])

Mobile advertising space rental

Tag: the of Can Borui Biotech stand out in treatment